Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Cancer Statistics by Demographics
     3.1 Prevalence, Incidences and Mortality (2008-2016)
     3.2 Leading States by Incidence
     3.3 Leading Cancers by Incidence
            3.3.1 Male Cancer Incidences
            3.3.2 Female Cancer Incidences
            3.3.3 Age-Group

4. Cancer Vaccines Market Outlook
     4.1 Market Analysis and Segmentation
     4.2 Key Product Analysis
            4.2.1 Provenge
                       4.2.1.1 Market Analysis
                       4.2.1.2 Restraints
            4.2.2 HPV Vaccine
                       4.2.2.1 Gardasil
                                      4.2.2.1.1 Market Analysis
                                      4.2.2.1.2 Restraints
                      4.2.2.2 Cervarix
                                     4.2.2.2.1 Market Analysis
                                     4.2.2.2.2 Restraints
            4.2.3 HBV Vaccines
                       4.2.3.1 Market Analysis
                       4.2.3.2 Market Restraints
                                     4.2.3.2.1 Engerix-B and Twinrix
                                     4.2.3.2.2 Recombivax HB and Comvax
                                     4.2.3.2.3 Pediarix

5. Potential Cancer Vaccine Candidates: An Opportunity Assessment
     5.1 Prophylactic Vaccine
     5.2 Therapeutic Vaccine
            5.2.1 Prostate Cancer
            5.2.2 Breast Cancer
            5.2.3 Lung Cancer
            5.2.4 Colorectal Cancer

6. Regulatory Environment
     6.1 Vaccine Approval Process
     6.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
            6.2.1 Considerations for both Early and Late Phase Clinical Trials
                      6.2.1.1 Patient Population
                      6.2.1.2 Monitoring the Immune Response
                      6.2.1.3 Biomarkers as Evidence of Efficacy
                      6.2.1.4 Adjuvants Used to Stimulate Immune Response
                      6.2.1.5 Multi-antigen Vaccines
                      6.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
                      6.2.1.7 Concomitant and Subsequent Therapies
            6.2.2 Considerations for Early Phase Clinical Trials
                       6.2.2.1 Starting Dose and Dosing Schedule
                       6.2.2.2 Booster and Maintenance Therapy
                       6.2.2.3 Dose Escalation
                       6.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
            6.2.3 Considerations for Late Phase Clinical Trials
                       6.2.3.1 Safety Profile from Early Phase Clinical Trials
                       6.2.3.2 Endpoints
                       6.2.3.3 Statistical Issues
                       6.2.3.4 Control Issues
                       6.2.3.5 Delayed Vaccine Effect
                       6.2.3.6 Autologous Vaccine Trials
                       6.2.3.7 Accelerated Approval Regulations

7. Competitive Landscape
     7.1 Merck & Co.
            7.1.1 Business Description
            7.1.2 Key Strategy Analysis
     7.2 GSK
            7.2.1 Business Description
            7.2.2 Key Strategy Analysis
     7.3 Dendreon
            7.3.1 Business Description
            7.3.2 Key Strategy Analysis
     7.4 Bavarian Nordic
            7.4.1 Business Description
            7.4.2 Key Strategy Analysis
     7.5 Celldex Therapeutics
            7.5.1 Business Description
            7.5.2 Key Strategy Analysis
     7.6 Kael-GemVax
            7.6.1 Business Description
            7.6.2 Key Strategy Analysis
     7.7 Oxford BioMedica
            7.7.1 Business Description
            7.7.2 Key Strategy Analysis
     7.8 Galena Biopharma
            7.8.1 Business Description
            7.8.2 Key Strategy Analysis